Tempo Therapeutics key facts
- Operator of a life science company intended to harness the power of immunomodulation and material science to transform the landscape of medical technology.
- It has raised $20.7M across 2 recorded rounds; the latest was Early Stage VC ($16.3M) in Mar 2024.
- Notable investors include US National Science Foundation, MedTech Innovator, National Institutes of Health, CONNECT(San Diego), Johnson & Johnson JJDC — 14 tracked in total.
- Tempo Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Mar 2024 ($16.3M sold to 26 investors).
- Status: Privately Held (backing).
Who backs Tempo Therapeutics
14+- ·The complete investor list: 14 names
- ·Watch Tempo Therapeutics: the Monday email on marks, rounds and moves
Tempo Therapeutics funding rounds
2 roundsHow much has Tempo Therapeutics raised?
Tempo Therapeutics has raised $20.7 million across 2 recorded rounds since 2015. The largest was a $3.8 million seed round in Jul 2015; the most recent was a $16.3 million early-stage round in Mar 2024.
Tempo Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently in Mar 2024 ($16.3 million sold to 26 investors).
Tempo Therapeutics investors
14 investors are on record for Tempo Therapeutics, including US National Science Foundation, MedTech Innovator, National Institutes of Health and CONNECT(San Diego). The early-stage round in Mar 2024 drew 26 investors.
About Tempo Therapeutics
Operator of a life science company intended to harness the power of immunomodulation and material science to transform the landscape of medical technology. The company's hydrogel uses cell-free synthetic materials that use geometric technology to unlock the body's regenerative capacity and control inflammation, enabling patients to achieve accelerated healing rates, reduced chronic tissue inflammation, and increased regenerative healing.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2013
- Employees
- 15
- Website
- tempothera.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Tempo Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.